TrialThe breast journal

Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.

Shaheenah Dawood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.